The U.S. Food and Drug Administration (FDA) has expanded its approval of Kalydeco (ivacaftor) to include cystic fibrosis (CF) patients with one of 23 additional rare mutations — more than tripling the number of mutations the oral drug may be used to treat from 10 to 33. But the decision’s…
News
Spyryx Biosciences will present two studies in Washington this week on SPX-101‘s ability to treat cystic fibrosis by clearing mucus from airways. One of the preclinical-trial studies it will discuss at the American Thoracic Society‘s annual convention showed that SPX-101 improved survival in several models of CF-like lung diseases.
Dalton and Arch Biopartners are partnering to manufacture AB569 for clinical trials involving cystic fibrosis (CF) patients with chronic, antibiotic-resistant bacterial lung infections. Under the agreement, the two will divide manufacturing tasks, including formulating the compound, putting it in containers safely, and doing quality-control testing. The drug will be…
A substance found in a Japanese cypress tree can deliver iron to cells that are unable to obtain it because of faulty proteins, a finding that has implications for cystic fibrosis, according to a study. Researchers said their molecular-prosthetics approach could not only address cystic fibrosis (CF), but also other conditions…
Researchers at TGV-inhalonix said their company’s drug, Mul-1867, has a powerful effect against clinical isolates of fungi in patients with cystic fibrosis (CF) and other severe lung infections. The study “In vitro activity of a novel compound, Mul-1867, against clinically significant fungi Candida spp. and Aspergillus spp.” appeared in the International Journal of Antimicrobial…
Mutated mice that inhaled SPX-101 lived longer, according to a new preclinical study that highlights the drug’s potential to clear mucus and hydrate airways in patients with cystic fibrosis (CF). The study, “SPX-101 is a Novel ENaC-targeted Therapeutic for Cystic Fibrosis that Restores Mucus Transport,” appeared in the American Journal of…
Savara has received U.S. and Canadian patents for its AeroVanc powdered, inhaled formulation of the antibiotic vancomycin hydrochloride, which combats treatment-resistant lung infections in cystic fibrosis (CF) patients. AeroVanc addresses the growing challenge of the methicillin-resistant Staphylococcus aureus (MRSA) bacteria, Savara said in a press release. The patents from the United States Patent and Trademark…
Scientists at Boston University’s Center for Regenerative Medicine have made two stem cell discoveries that could help doctors treat cystic fibrosis (CF) without having to resort to transplants. They prevented stem cells from creating cells for a lot of organs at once and producing only the lung cells they need…
Fifteen non-profit groups in seven countries will receive Cystic Fibrosis Circle of Care project grants totaling nearly $1 million this year, the program’s sponsor, Vertex Pharmaceuticals, announced. The grants, now in their third year, go to medical, academic, patient, and community organizations serving the cystic fibrosis (CF) community. Since the program started in…
A more light weight and mobile vest for people with cystic fibrosis or related diseases who need help with airway clearance is now available for use at home or while traveling through its developer, Hill-Rom, the company announced. The system is based on a mobile vest created by a CF patient. A number of…
Your CF Community
Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.